UPDATE: BMO Capital Markets Upgrades Bristol-Myers Squibb on More Positive Outlook

In a report published Monday, BMO Capital Markets analyst Alex Arfaei upgraded the rating on Bristol-Myers Squibb (NYSE: BMY ) from Market Perform to Outperform, and raised the price target from $56.00 to $60.00. In the report, BMO Capital Markets noted, “We are upgrading BMY to Outperform from Market Perform